Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 19/20 | 1.00 |
| ▸ | CDK5 | Q00535 | 16/20 | 1.00 |
| ▸ | CDK5R1 | Q15078 | 16/20 | 1.00 |
| ▸ | GSK3A | P49840 | 15/20 | 1.00 |
| ▸ | CCNB2 | O95067 | 6/20 | 0.76 |
| ▸ | CDK1 | P06493 | 6/20 | 0.76 |
| ▸ | CCNB1 | P14635 | 6/20 | 0.76 |
| ▸ | CCNB3 | Q8WWL7 | 6/20 | 0.76 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.76 |
| ▸ | CDK2 | P24941 | 2/20 | 0.76 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.76 |
| ▸ | ABL1 | P00519 | 1/20 | 0.76 |
| ▸ | LCK | P06239 | 1/20 | 0.76 |
| ▸ | FYN | P06241 | 1/20 | 0.76 |
| ▸ | PIM1 | P11309 | 1/20 | 0.76 |
| ▸ | FLT4 | P35916 | 1/20 | 0.76 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.76 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22570392 | 0.86 | GSK3B (0.76) | GSK3BCDK5CDK5R1GSK3ACCNB2 | |
| SCHEMBL379389 | 0.86 | GSK3B (1.00) | GSK3BCDK5CDK5R1GSK3ACCNB2 | |
| SCHEMBL378921 | 0.86 | GSK3B (1.00) | GSK3BCDK5CDK5R1GSK3ACCNB2 | |
| SCHEMBL379540 | 0.86 | GSK3B (1.00) | GSK3BCDK5CDK5R1GSK3ACCNB2 | |
| Azakenpaullone SCHEMBL29363781 | 0.86 | GSK3B (1.00) | GSK3BCDK5CDK5R1GSK3ACCNB2 | |
| SCHEMBL378333 | 0.86 | GSK3B (1.00) | GSK3BCDK5CDK5R1GSK3ACCNB2 | |
| Azakenpaullone SCHEMBL378920 | 0.86 | GSK3B (1.00) | GSK3BCDK5CDK5R1GSK3ACCNB2 | |
| SCHEMBL379533 | 0.85 | GSK3B (1.00) | GSK3BCDK5CDK5R1GSK3ACCNB2 | |
| SCHEMBL379385 | 0.85 | GSK3B (1.00) | GSK3BCDK5CDK5R1GSK3ACCNB2 | |
| SCHEMBL24393915 | 0.83 | GSK3B (0.74) | GSK3BCDK5CDK5R1GSK3ACCNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1879591-B1 | USE OF AZAPAULLONES FOR PREVENTING AND TREATING PANCREATIC AUTOIMMUNE DISORDERS | DEVELOGEN AG (DE) | 2012-01-25 | — | — | EP | disclosed |
| EP-1879591-B1 | USE OF AZAPAULLONES FOR PREVENTING AND TREATING PANCREATIC AUTOIMMUNE DISORDERS | DEVELOGEN AG (DE) | 2012-01-25 | — | — | EP | disclosed |
| US-7968535-B2 | Antidiabetic agents; neurodegenerative disorders; mixture with immunosuppresants | DEVELOGEN ATKIENGESELLSCHAFT (DE) | 2011-06-28 | — | — | US | disclosed |
| US-7968535-B2 | Antidiabetic agents; neurodegenerative disorders; mixture with immunosuppresants | DEVELOGEN ATKIENGESELLSCHAFT (DE) | 2011-06-28 | — | — | US | disclosed |
| US-20080287423-A1 | Use of Azapaullones For Preventing and Treating Pancreatic Autoimmune Disorders | EVOTEC INTERNATIONAL GMBH (DE) | 2008-11-20 | — | — | US | disclosed |
| US-20080287423-A1 | Use of Azapaullones For Preventing and Treating Pancreatic Autoimmune Disorders | EVOTEC INTERNATIONAL GMBH (DE) | 2008-11-20 | — | — | US | disclosed |
| US-20080287423-A1 | Use of Azapaullones For Preventing and Treating Pancreatic Autoimmune Disorders | EVOTEC INTERNATIONAL GMBH (DE) | 2008-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287423-A1 | Use of Azapaullones For Preventing and Treating Pancreatic Autoimmune Disorders | IAPP, RNASE1, AMY2A | GSK3B 2669/4885CDK5 2145/4885CDK5R1 2358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.